Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report


  • Karim Souaid
  • Bénédicte Oulès
  • Pierre Sohier
  • Lydia Deschamps
  • Sélim Aractingi Department of Dermatology, Hôpital Cochin, AP-HP, AP-HP Centre-Université de Paris, 89 rue d’Assas, FR-75006 Paris, France https://orcid.org/0000-0002-7766-2673
  • Nicolas Dupin




chilblains, COVID-19, SARS-CoV-2 spike protein, COVID-19 mRNA vaccine, IFN


Abstract is missing (Short communication)


Download data is not yet available.


Matar S, Oulès B, Sohier P, Chosidow O, Beylot-Barry M, Dupin N, et al. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatology Venereol 2020; 34: e686-e689.

https://doi.org/10.1111/jdv.16775 DOI: https://doi.org/10.1111/jdv.16775

Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, et al. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing*. Br J Dermatol 2020; 183: 866-874.

https://doi.org/10.1111/bjd.19377 DOI: https://doi.org/10.1111/bjd.19377

Aschoff R, Zimmermann N, Beissert S, Günther C. Type I interferon signature in chilblain-like lesions associated with the COVID-19 pandemic. Dermatopathology 2020; 7: 57-63.

https://doi.org/10.3390/dermatopathology7030010 DOI: https://doi.org/10.3390/dermatopathology7030010

Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol 2021; 157: 202-206.

https://doi.org/10.1001/jamadermatol.2020.4324 DOI: https://doi.org/10.1001/jamadermatol.2020.4324

Sohier P, Matar S, Meritet J-F, Laurent-Roussel S, Dupin N, Aractingi S. Histopathologic features of chilblainlike lesions developing in the setting of the coronavirus disease 2019 (COVID-19) pandemic. Arch Pathol Lab Med 2021; 145: 137-144.

https://doi.org/10.5858/arpa.2020-0613-SA DOI: https://doi.org/10.5858/arpa.2020-0613-SA

McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46-55.

https://doi.org/10.1016/j.jaad.2021.03.092 DOI: https://doi.org/10.1016/j.jaad.2021.03.092




How to Cite

Souaid, K., Oulès, B., Sohier, P., Deschamps, L., Aractingi, S., & Dupin, N. (2021). Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report. Acta Dermato-Venereologica, 101(11), adv00589. https://doi.org/10.2340/00015555-3888